Welcome to our dedicated page for LAVA Therapeutics news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics stock.
LAVA Therapeutics N.V. reports developments as a clinical-stage immuno-oncology company built around its proprietary Gammabody® platform of bispecific gamma delta T cell engagers. Company news centers on programs for hematologic malignancies and solid tumors, including LAVA-1266 and partnered candidates JNJ-89853413 and PF-08046052.
Recurring updates also cover clinical and regulatory disclosures, partnership milestones, operating and financial results, restructuring actions, strategic-alternative reviews, material agreements, shareholder matters and corporate-status developments related to its common shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
LAVA Therapeutics N.V. (Nasdaq: LVTX) has announced promising clinical data from its ongoing Phase 1/2a trials for LAVA-051 and LAVA-1207, focusing on hematologic malignancies and metastatic castration-resistant prostate cancer. LAVA-051 demonstrated a favorable safety profile and initial anti-tumor activity in patients with chronic lymphocytic leukemia and multiple myeloma. Similarly, initial data for LAVA-1207 indicated a favorable safety profile with signs of clinical activity, including stabilized or decreased PSA levels in heavily pre-treated patients. Financially, LAVA reported a strong balance sheet with cash and investments totaling $132.9 million, expected to sustain operations through 2026. Additionally, a license agreement with Seagen for LAVA-1223 provides $50 million upfront and up to $650 million in potential milestones.